Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32421451)

  • 1. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
    Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
    Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
    El Dika I; Ilson DH
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
    Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies.
    Hanssens C; Mouna O; Meyers M; Hendlisz A
    Curr Opin Oncol; 2024 Jul; 36(4):320-325. PubMed ID: 38726837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of autophagy in HER2-targeted therapy.
    Janser FA; Tschan MP; Langer R
    Swiss Med Wkly; 2019 Oct; 149():w20138. PubMed ID: 31656036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
    Stravodimou A; Voutsadakis IA
    Anticancer Res; 2020 Sep; 40(9):4829-4841. PubMed ID: 32878771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
    Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
    Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.